着床前検査、保険適用見送り　不妊治療で中医協に提案―厚労省

　厚生労働省は２６日、４月から開始する不妊治療の保険適用に関し、受精卵の染色体異常を調べる「着床前検査」への適用を見送る案を中央社会保険医療協議会（厚労相の諮問機関、中医協）に示した。一方、人工授精や体外受精には適用。体外受精では治療開始時点で４３歳未満の女性を対象とするなどの条件を設ける。中医協は２月上旬にも、不妊治療への保険適用を含めた診療報酬改定案をまとめる。
　着床前検査は流産や不妊につながる染色体異常がない受精卵を選んで戻すため、「命の選別につながる」との批判が出ている。日本産科婦人科学会も、保険対象診療と併用できる「先進医療」での申請を目指す方針を示しており、厚労省は倫理面での問題を踏まえ、今回は適用外とした。（2022/01/26-11:26）

Japan's health ministry on Wednesday unveiled a plan for public health insurance not to cover the preimplantation screening of eggs fertilized in vitro for chromosomal abnormalities.
   The plan was presented to the Central Social Insurance Medical Council, which advises the health minister, ahead of the April start of public health insurance coverage for fertility treatment, including artificial insemination and in vitro fertilization.
   For fertility treatment, the insurance coverage will be available to women who are under age 43 when they begin treatment.
   In early February at the earliest, the council will draw up a proposal to revise the medical service fees under the public health insurance program, including the addition of fertility treatment to the list of items covered by the insurance.
   Critics say that preimplantation screening prompts the selection of life because the procedure selects and transfers to the uterus fertilized eggs without chromosomal abnormalities that can lead to miscarriage or infertility.